AZT ArcticZymes Technologies ASA

2.182USD21.10 NOK · OSL+0.48%Mkt Cap: 111.45M USDP/E: 78.15

ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp a…

Key Statistics

Company
Market Cap111.45M USD
Enterprise Value85.21M USD
Revenue (TTM)14.14M USD
Gross Profit11.14M USD
Net Income (TTM)1.01M USD
Revenue/Share0.27 USD
Last Price2.182 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees50
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010014632
Valuation
P/E (Trailing)78.15
P/E (Forward)43.04
PEG—
EV/EBITDA53.60
EV/Revenue6.03
P/S7.88
P/B3.08
EPS (TTM)0.03 USD
EPS (Forward)0.05 USD
52W Range
1.89334% of range2.751
52W High2.751 USD
52W Low1.893 USD
Profitability
Gross Margin95.68%
Oper. Margin8.00%
EBITDA Margin11.24%
Profit Margin8.65%
ROE2.88%
ROA2.70%
ROIC1.35%
ROCE0.77%
Growth
Revenue Growth11.10%
Earnings Growth-50.00%
Cash Flow & Leverage
Operating CF2.67M USD
CapEx (TTM)376.68K USD
FCF Margin4.37%
FCF Yield0.55%
Net Debt-26.24M USD
Net Debt/EBITDA-16.51
Net Debt/FCF-42.43
Balance Sheet
Debt/Equity0.02
Current Ratio15.54
Quick Ratio14.60
Book Value/Sh0.71 USD
Cash/Share0.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.793 USD
Upside (mean)+28.0%
Target Range2.793 USD – 2.793 USD
# Analysts1
Ownership
Shares Out.51.07M
Float41.94M
Insiders17.41%
Institutions13.81%
Technical
SMA 502.131 (+2.4%)
SMA 2002.126 (+2.7%)
Beta0.60
S&P 52W Chg12.00%
Avg Vol (30d)60.26K
Avg Vol (10d)101.74K
Technical Indicators
RSI (14)50.1
MACD0.2884
MACD Signal0.3877
MACD Hist.-0.0993
BB Upper2.348 USD
BB Middle2.212 USD
BB Lower2.077 USD
BB Width12.24%
ATR (14)0.1046 USD
Vol Ratio (20d)0.25x

About ArcticZymes Technologies (OSL: AZT)

›

ArcticZymes Technologies (OSL: AZT) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 50 employees.

The shares were at 21.10 NOK on 19 November 2026, down 12.4% over 52 weeks. Its 52-week range is 18.30 NOK to 26.60 NOK: the price is 20.7% below the high and 15.3% above the low.

At a market capitalisation of 1.08B NOK, it trades at 78.1 times trailing earnings and 43.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a premium of 133% for AZT.

ArcticZymes Technologies reports return on equity of 2.9%, an operating margin of 8.0% and revenue up 11.1% year over year.

It holds more cash than debt, a net cash position of 253.74M NOK. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 27.00 NOK is 28.0% above the current price. The next earnings report is expected on 11 February 2027.